243 related articles for article (PubMed ID: 37665349)
1. Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives.
Krecak I; Verstovsek S; Lucijanic M
Ann Hematol; 2024 May; 103(5):1513-1523. PubMed ID: 37665349
[TBL] [Abstract][Full Text] [Related]
2. Reappraisal of cardiovascular risk factors in patients with chronic myeloproliferative neoplasms.
Krecak I; Verstovsek S; Lucijanic M
Clin Adv Hematol Oncol; 2023 Oct; 21(10):541-548. PubMed ID: 37948590
[TBL] [Abstract][Full Text] [Related]
3. Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.
Soderquist CR; Ewalt MD; Czuchlewski DR; Geyer JT; Rogers HJ; Hsi ED; Wang SA; Bueso-Ramos CE; Orazi A; Arber DA; Hexner EO; Babushok DV; Bagg A
Mod Pathol; 2018 May; 31(5):690-704. PubMed ID: 29327708
[TBL] [Abstract][Full Text] [Related]
4. BCR-ABL1--negative myeloproliferative neoplasms: a review of molecular biology, diagnosis, and treatment.
Vakil E; Tefferi A
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S37-45. PubMed ID: 22035746
[TBL] [Abstract][Full Text] [Related]
5. BCR-ABL negative myeloproliferative neoplasia: a review of involved molecular mechanisms.
Koopmans SM; Schouten HC; van Marion AM
Histol Histopathol; 2015 Feb; 30(2):151-61. PubMed ID: 25196073
[TBL] [Abstract][Full Text] [Related]
6. Sequential Development of JAK2V617F Mutation and BCR-ABL1 Fusion in Individual Patients With Myeloproliferative Neoplasms.
Zhao Y; Reddi D; McCracken J; Iranzad N; Rehder C; Neff J; Wang E
Arch Pathol Lab Med; 2022 Jun; 146(6):710-717. PubMed ID: 34506622
[TBL] [Abstract][Full Text] [Related]
7. [JAK2 V617F and exon 12 genetic variations in Korean patients with BCR/ABL1-negative myeloproliferative neoplasms].
Kim JT; Cho YG; Choi SI; Lee YJ; Kim HR; Jang SJ; Moon DS; Park YJ; Park G
Korean J Lab Med; 2010 Dec; 30(6):567-74. PubMed ID: 21157140
[TBL] [Abstract][Full Text] [Related]
8. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice.
Walz C; Ahmed W; Lazarides K; Betancur M; Patel N; Hennighausen L; Zaleskas VM; Van Etten RA
Blood; 2012 Apr; 119(15):3550-60. PubMed ID: 22234689
[TBL] [Abstract][Full Text] [Related]
9. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
Ahmed RZ; Rashid M; Ahmed N; Nadeem M; Shamsi TS
Asian Pac J Cancer Prev; 2016; 17(3):923-6. PubMed ID: 27039813
[TBL] [Abstract][Full Text] [Related]
10. Successful Treatment of a Patient with Chronic Myelogenous Leukemia with Concurrent Janus Kinase 2 (JAK2) R795S Mutation and Breakpoint Cluster Region-ABL1 (BCR-ABL1) Fusion: A Case Report and Literature Review.
Yue Y; Wei W; Guo Y; Wang F; Dong W; Liu Y; Lin Y; Cao Y; Gu W
Am J Case Rep; 2020 Oct; 21():e925151. PubMed ID: 33021971
[TBL] [Abstract][Full Text] [Related]
11. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS
Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
[TBL] [Abstract][Full Text] [Related]
12. Chronic kidney disease in the BCR-ABL1-negative myeloproliferative neoplasm: a single-center retrospective study.
Baek SW; Moon JY; Ryu H; Choi YS; Song IC; Lee HJ; Yun HJ; Kim S; Jo DY
Korean J Intern Med; 2018 Jul; 33(4):790-797. PubMed ID: 28298076
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis- and Prognosis-Related Gene Alterations in
Morishita S; Komatsu N
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629188
[No Abstract] [Full Text] [Related]
14. Rare Case of Accelerated-Phase Chronic Myeloid Leukemia Diagnosed During Treatment for JAK2 V617F-Positive Primary Myelofibrosis.
Ryu J; Chu D; Park B; Kim M; Cho YU; Hwang SH; Jang S; Seo EJ; Lee JH; Park CJ
Lab Med; 2022 Nov; 53(6):e140-e144. PubMed ID: 35243502
[TBL] [Abstract][Full Text] [Related]
15. The Prevalence of JAK2, MPL, and CALR Mutations in Chinese Patients With BCR-ABL1-Negative Myeloproliferative Neoplasms.
Lin Y; Liu E; Sun Q; Ma J; Li Q; Cao Z; Wang J; Jia Y; Zhang H; Song Z; Ai X; Shi L; Feng X; Li C; Wang J; Ru K
Am J Clin Pathol; 2015 Jul; 144(1):165-71. PubMed ID: 26071474
[TBL] [Abstract][Full Text] [Related]
16. The impact of CYP2D6*4 and GSTP1 Ile105Val polymorphisms on the susceptibility to develop BCR-ABL1 negative myeloproliferative neoplasms.
Daglar-Aday A; Akadam-Teker B; Yonal-Hindilerden I; Dermenci H; Sahin E; Hindilerden F; Yilmaz-Aydogan H; Ozturk O; Yavuz AS
Mol Biol Rep; 2020 Oct; 47(10):7413-7420. PubMed ID: 32918123
[TBL] [Abstract][Full Text] [Related]
17. Clinical and Molecular Attributes of Patients With BCR/ABL1-negative Myeloproliferative Neoplasms in India: Real-world Data and Challenges.
Singh S; Kaur K; Paul D; Jain K; Singh J; Narang V; Garg B; Sood N; Dhillon B
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e569-e578. PubMed ID: 33757770
[TBL] [Abstract][Full Text] [Related]
18. Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices.
Tefferi A
Leuk Lymphoma; 2010 Apr; 51(4):576-82. PubMed ID: 20214447
[TBL] [Abstract][Full Text] [Related]
19. Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms.
Mughal TI; Lion T; Abdel-Wahab O; Mesa R; Scherber RM; Perrotti D; Mauro M; Verstovsek S; Saglio G; Van Etten RA; Kralovics R
Hematol Oncol; 2018 Dec; 36(5):740-748. PubMed ID: 30074634
[TBL] [Abstract][Full Text] [Related]
20. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
Pardanani A; Tefferi A
Leuk Lymphoma; 2014 Dec; 55(12):2706-11. PubMed ID: 25520049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
